Program Committee
-
Rei Maeda Consultant
Independent Consultant for Drug PV, Japan -
Fumiyo Aoki Team Manager, Pharmacovigilance
AbbVie GK, Japan -
Hiroya Asou, MD, PHD, MBA Senior Medical Advisor, Global Patient Safety Japan
Eli Lilly Japan K.K., Japan -
Kasumi Daidoji, PHD, RPH Associate Director, Clinical Planning & Development Dept., Medical Headquarters
Eisai Company, Ltd., Japan -
Kazuhiko Ishida, MSC, RPH Director, Pharmacovigilance
Astellas Pharma Inc., Japan -
Rie Matsui, RPH Senior Director, Regional Labeling Head for APAC
Pfizer R&D Japan G.K., Japan -
Kou Miyakawa Director
Takeda Pharmaceutical Company Limited, Japan -
Hiroyuki Murakami, PHD Duputy Review Director, Office of New Drug I
Pharmaceuticals and Medical Devices Agency (PMDA), Japan -
Mitsuo Saito, PHD Technical Advisor
Institute For Health Vigilance, Japan -
Junko Sato, PHD Associate Executive Director
Pharmaceuticals and Medical Devices Agency (PMDA), Japan -
Tomoko Yamada Director, Safety risk management, Pharmacovigilance
MSD K.K., Japan
Have an account?